Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age at least 6 months,
- weight at least 5 kg,
- residing in one of the four countries (Mali, Cameroon, Sudan, Rwanda),
- able to receive oral treatment,
- having an axillary body temperature of more than 37,5 degrees Celsius or history of fever within the proceeding 24 hours,
- suffering from a mono specific P. falciparum infection with a parasite density between 2000 and 200000 asexual forms per micro litre of blood.
Exclusion Criteria:
- presence of severe or complicated malaria (WHO 2000),
- severe concomitant pathology or one that needs a medical follow-up incompatible with the study,
- allergic to one of the drugs involved in this study,
- pregnant (reported pregnancy, detected clinically or with the β HCG test),
- use of one of the anti-malaria drugs involved in this study during 28 days preceding inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PCR corrected Adequate Clinical and Parasitological Response
Time Frame: on day 28 (follow-up period)
|
on day 28 (follow-up period)
|
|
Early treatment failure
Time Frame: between day 0 and day 3
|
between day 0 and day 3
|
|
Late clinical failure
Time Frame: between day 4 and day 28
|
between day 4 and day 28
|
|
Late parasitological failure
Time Frame: between day 7 and day 28
|
between day 7 and day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Parasitic clearance
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Fever clearance
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Parasitological re-infection
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Gametocyte carriage
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Safety - Adverse events
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Haemoglobin levels
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
|
Clinical and biological tolerance (Haemogram + Lever tests)
Time Frame: 28 day follow-up period
|
28 day follow-up period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Issaka Sagara, Dr, University of Bamako, Mali
- Principal Investigator: Wilfred F Mbacham, Dr, University Yaoundé, Cameroon
- Principal Investigator: Ishag A Adam, Dr, University of Khartoum, Sudan
- Principal Investigator: Stephen Rulisa, Dr, Kigali Central University Hospital, Rwanda
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2005/57/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.